Efgartigimod in Patients with Generalized Myasthenia Gravis Refractory or Intolerant to IVIg - PubMed
17 hours ago
- #Myasthenia Gravis
- #FcRn Inhibitors
- #Efgartigimod
- Efgartigimod (EFG) assessed in real-world AChR-positive generalized myasthenia gravis (gMG) patients refractory or intolerant to IVIg.
- Significant clinical improvement observed in MG-ADL and QMG scores after one treatment cycle; responder rates were 84.6% (MG-ADL reduction >2) and 69.2% (QMG reduction >3).
- EFG showed rapid benefit and favorable tolerability, with one patient achieving minimal symptom expression and a mean reduction in daily prednisone dose of 6.9 mg.